Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CDK4 | P11802 | 1/20 | 0.31 |
| ▸ | CCND1 | P24385 | 1/20 | 0.31 |
| ▸ | TNF | P01375 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5800131 | 0.84 | TNF (0.34) | KDM4ELMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9879567 | 0.75 | KDM4E (0.34) | KDM4ELMNAHTTATM | |
| SCHEMBL7657126 | 0.75 | CYP2A6 (0.32) | KDM4ELMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL5894548 | 0.74 | CA12 (0.31) | CA12CA1CA2CA9 | |
| SCHEMBL9531 | 0.73 | ATM (0.48) | ATM | |
| SCHEMBL5894811 | 0.72 | — | — | |
| Water SCHEMBL5786021 | 0.72 | ATM (0.46) | ATM | |
| SCHEMBL27684621 | 0.72 | ATM (0.46) | ATM | |
| Fluoride SCHEMBL27608168 | 0.72 | ATM (0.46) | ATM | |
| Hydrochloric Acid SCHEMBL7370284 | 0.72 | BCHE (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4363043-B1 | COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-04-22 | — | — | EP | claimed |
| US-20240316012-A1 | METHODS FOR TREATING LYMPHOMA | NORTHWESTERN UNIVERSITY (US) | 2024-09-26 | — | — | US | claimed |
| US-20240219403-A1 | METHODS FOR INHIBITING KRAS ONCOPROTEIN THROUGH ENHANCED GTPASE ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-07-04 | — | — | US | claimed |
| WO-2022217073-A1 | METHODS FOR INHIBITING KRAS ONCOPROTEIN THROUGH ENHANCED GTPASE ACTIVITY | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-10-13 | — | — | WO | claimed |
| WO-2022093770-A1 | COMBINATION THERAPY WITH PI3K-AKT-MTOR INHIBITORS AND FERROPTOSIS INDUCING AGENTS TO TREAT CANCER | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-05-05 | — | — | WO | claimed |
| EP-0234516-B1 | 1,6-NAPHTHYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICINE CONTAINING THEM FOR THE TREATMENT OF VASCULAR DISEASES | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1992-04-29 | — | — | EP | claimed |
| EP-0173933-B1 | 1,6-NAPHTHYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICAMENT CONTAINING THEM | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1989-11-29 | — | — | EP | claimed |
| EP-0133530-B1 | 1,6-NAPHTHYRIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND MEDICAMENTS CONTAINING THEM | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1989-03-15 | — | — | EP | claimed |
| EP-4729067-A2 | ELECTRODE ASSEMBLY FOR APPLYING TUMOR TREATING FIELDS WITH A SHEET OF ANISOTROPIC MATERIAL | Novocure GmbH (CH) | 2026-04-22 | — | — | EP | disclosed |
| US-12415844-B2 | BCMA specific VCAR compositions and methods for use | POSEIDA THERAPEUTICS, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-20250171518-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | CITY OF HOPE | 2025-05-29 | — | — | US | disclosed |
| US-12281062-B2 | Light induced catalytic C—H oxygenation of alkanes | Ariel Scientific Innovations Ltd. (IL) | 2025-04-22 | — | — | US | disclosed |
| WO-2025072355-A1 | METHODS FOR AND COMPOSITIONS OF NON-PEG BIOCONJUGATES WITH ULTRA-HIGH DRUG-TO-AGENT RATIO | BIOHYBRID SOLUTIONS HOLDINGS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| US-20250025473-A1 | CELL IMPERMEABLE KINASE INHIBITORS TO TREAT SARS-COV-2 AND/OR HSV VIRAL INFECTIONS | ALBERT EINSTEIN COLLEGE MEDICINE (US) | 2025-01-23 | — | — | US | disclosed |
| US-4698341-A | Use of 1,6-naphthyridinone derivatives in treating pulmonary thrombosis | GODECKE AKTIENGESELLSCHAFT (DE) | 1987-10-06 | — | — | US | disclosed |
| US-4698341-A | Use of 1,6-naphthyridinone derivatives in treating pulmonary thrombosis | GODECKE AKTIENGESELLSCHAFT (DE) | 1987-10-06 | — | — | US | disclosed |
| EP-0234516-A1 | 1,6-Naphthyridine derivatives, process for their preparation and medicine containing them for the treatment of vascular diseases | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1987-09-02 | — | — | EP | disclosed |
| EP-0189898-A1 | 1,6-Nephthyridinone derivatives and process for their preparation | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1986-08-06 | — | — | EP | disclosed |
| EP-0173933-A1 | 1,6-Naphthyridine derivatives, process for their preparation and medicament containing them | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1986-03-12 | — | — | EP | disclosed |
| EP-0133530-A2 | 1,6-Naphthyridinone derivatives, process for their preparation, and medicaments containing them | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1985-02-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171518-A1 | METHODS FOR PREPARING CELLS FOR ADOPTIVE T CELL THERAPY | CD4, ICOS, CD2 | KDM4E 3828/4885LMNA 4190/4885CYP1A2 4635/4885 |
| US-20250025473-A1 | CELL IMPERMEABLE KINASE INHIBITORS TO TREAT SARS-COV-2 AND/OR HSV VIRAL INFECTIONS | PDPK1, DAPK1, DAPK2 | KDM4E 2892/4885LMNA 4271/4885CYP1A2 4317/4885 |
| US-12281062-B2 | Light induced catalytic C—H oxygenation of alkanes | CBR1, CBR3, HAO2 | KDM4E 1939/4885LMNA 1169/4885CYP1A2 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.